Neogen (NEOG) Lags Q3 Earnings and Revenue Estimates

Company Performance - Neogen reported quarterly earnings of $0.10 per share, missing the Zacks Consensus Estimate of$ 0.13 per share, and down from $0.12 per share a year ago, representing an earnings surprise of -23.08% [1] - The company posted revenues of$ 220.98 million for the quarter ended February 2025, missing the Zacks Consensus Estimate by 0.92%, and down from $228.81 million year-over-year [2] - Neogen has not surpassed consensus EPS estimates over the last four quarters, although it has topped consensus revenue estimates three times during the same period [2] Stock Performance - Neogen shares have declined approximately 42% since the beginning of the year, compared to a decline of -15.3% for the S&P 500 [3] - The current Zacks Rank for Neogen is 4 (Sell), indicating expectations for the stock to underperform the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is$ 0.14 on revenues of $237.04 million, and for the current fiscal year, it is$ 0.45 on revenues of $908.28 million [7] - The outlook for the Medical - Products industry, to which Neogen belongs, is currently in the bottom 33% of over 250 Zacks industries, which may negatively impact stock performance [8]